Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9419643 | 0.91 | CA1 (0.40) | P2RX4ALDH1A1ALOX15 | |
| SCHEMBL6045312 | 0.80 | PIM1 (0.56) | PIM1TP53MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6045308 | 0.80 | PIM1 (0.56) | PIM1TP53MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6045322 | 0.74 | USP2 (0.52) | P2RX4TP53ALDH1A1ALOX15 | |
| SCHEMBL6045372 | 0.73 | USP2 (0.51) | P2RX4TP53ALDH1A1ALOX15 | |
| SCHEMBL6045315 | 0.73 | MEN1 (0.53) | P2RX4TP53MEN1ALDH1A1MAPT | |
| SCHEMBL6045244 | 0.72 | PIM1 (0.41) | PIM1MEN1KMT2A | |
| Pyrrolidine SCHEMBL6045325 | 0.68 | MAPT (0.55) | PIM1P2RX4MEN1ALDH1A1CYP1A2 | |
| Piperidine SCHEMBL6045374 | 0.67 | MAPT (0.54) | PIM1P2RX4MEN1ALDH1A1CYP1A2 | |
| Morpholine SCHEMBL6045317 | 0.66 | MAPT (0.53) | PIM1P2RX4MEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241108-A1 | Substituted phenoxazines and acridones as inhibitors of AKT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241108-A1 | Substituted phenoxazines and acridones as inhibitors of AKT | AKT1S1, AKT3, PIK3CA | PIM1 572/4885P2RX4 1184/4885TP53 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.